echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > APSB Shanghai Institute of Medicine Li Jia/Xiong Bing team cooperates to develop selective DDRs inhibitors for idiopathic pulmonary fibrosis

    APSB Shanghai Institute of Medicine Li Jia/Xiong Bing team cooperates to develop selective DDRs inhibitors for idiopathic pulmonary fibrosis

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pulmonary fibrosis is a progressive, diffuse pulmonary inflammatory disease characterized by chronic non-substantial damage and fibrosis caused by a variety of unknown causes


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.